Literature DB >> 22688760

Genetic manipulation of poxviruses using bacterial artificial chromosome recombineering.

Matthew G Cottingham1.   

Abstract

Traditional methods for genetic manipulation of poxviruses rely on low-frequency natural recombination in virus-infected cells. Although these powerful systems represent the technical foundation of current knowledge and applications of poxviruses, they require long (≥ 500 bp) flanking sequences for homologous recombination, an efficient viral selection method, and burdensome, time-consuming plaque purification. The beginning of the twenty-first century has seen the application of bacterial artificial chromosome (BAC) technology to poxviruses as an alternative method for their genetic manipulation, following the invention of a long-sought-after method for deriving a BAC clone of vaccinia virus (VAC-BAC) by Arban Domi and Bernard Moss. The key advantages of the BAC system are the ease and versatility of performing genetic manipulation using bacteriophage λ Red recombination (recombineering), which requires only ∼50 bp homology arms that can be easily created by PCR, and which allows seamless mutations lacking any marker gene without having to perform transient-dominant selection. On the other hand, there are disadvantages, including the significant setup time, the risk of contamination of the cloned genome with bacterial insertion sequences, and the nontrivial issue of removal of the BAC cassette from derived viruses. These must be carefully weighed to decide whether the use of BACs will be advantageous for a particular application, making pox-BAC systems likely to complement, rather than supplant, traditional methods in most laboratories.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688760     DOI: 10.1007/978-1-61779-876-4_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Authors:  Michael Wolferstätter; Marc Schweneker; Michaela Späth; Susanne Lukassen; Marieken Klingenberg; Kay Brinkmann; Ursula Wielert; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2014-10-08       Impact factor: 5.103

2.  Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.

Authors:  Toritse Orubu; Naif Khalaf Alharbi; Teresa Lambe; Sarah C Gilbert; Matthew G Cottingham
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

3.  Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping.

Authors:  Naif Khalaf Alharbi; Senthil K Chinnakannan; Sarah C Gilbert; Simon J Draper
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 4.  CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.

Authors:  Arinze Okoli; Malachy I Okeke; Morten Tryland; Ugo Moens
Journal:  Viruses       Date:  2018-01-22       Impact factor: 5.048

5.  Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.

Authors:  Alexandra J Spencer; Matthew G Cottingham; Jennifer A Jenks; Rhea J Longley; Stefania Capone; Stefano Colloca; Antonella Folgori; Riccardo Cortese; Alfredo Nicosia; Migena Bregu; Adrian V S Hill
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

6.  Construction and characterization of bacterial artificial chromosomes harboring the full-length genome of a highly attenuated vaccinia virus LC16m8.

Authors:  Tomoki Yoshikawa; Hikaru Fujii; Akiko Okutani; Miho Shibamura; Natsumi Omura; Kazutaka Egawa; Hirofumi Kato; Takuya Inagaki; Shizuko Harada; Souichi Yamada; Shigeru Morikawa; Masayuki Saijo
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.